{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:01:42Z","timestamp":1793826102584,"version":"4.6.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1038\/s41423-019-0245-x","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T12:04:56Z","timestamp":1560945896000},"page":"410-411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["IFN-\u03b3 upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1\/PD-L1 blockade"],"prefix":"10.1038","volume":"17","author":[{"given":"Maria Pia","family":"Pistillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Carosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Banelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Varesano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Ven\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Poggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Roncella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,19]]},"reference":[{"key":"245_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41423-018-0086-z","volume":"16","author":"X Li","year":"2019","unstructured":"Li, X., Song, W., Shao, C., Shi, Y. & Han, W. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cell. Mol. Immunol. 16, 28\u201339 (2019).","journal-title":"Cell Mol. Immunol."},{"key":"245_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jtho.2017.03.018","volume":"12","author":"S Lantuejoul","year":"2017","unstructured":"Lantuejoul, S., Le Stang, N., Damiola, F., Scherpereel, A. & Galateau-Sall\u00e9, F. PD-L1 testing for immune checkpoint inhibitors in mesothelioma: for want of anything better? J. Thorac. Oncol. 12, 778\u2013781 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"245_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/cas.13424","volume":"109","author":"K Mimura","year":"2018","unstructured":"Mimura, K. et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 109, 43\u201353 (2018).","journal-title":"Cancer Sci."},{"key":"245_CR4","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","volume":"12","author":"SC Kao","year":"2017","unstructured":"Kao, S. C. et al. Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma. J. Thorac. Oncol. 12, 1421\u20131433 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"245_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00262-014-1609-9","volume":"64","author":"L Calabr\u00f2","year":"2015","unstructured":"Calabr\u00f2, L. et al. CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic\/target therapy? Cancer Immunol. Immunother. 64, 105\u2013112 (2015).","journal-title":"Cancer Immunol. Immunother."},{"key":"245_CR6","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-10-0250","volume":"17","author":"X Frigola","year":"2011","unstructured":"Frigola, X. et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin. Cancer Res. 17, 1915\u20131923 (2011).","journal-title":"Clin. Cancer Res."},{"key":"245_CR7","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1084\/jem.20180870","volume":"216","author":"B Gong","year":"2019","unstructured":"Gong, B. et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J. Exp. Med. 216, 982\u20131000 (2019).","journal-title":"J. Exp. Med"},{"key":"245_CR8","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","volume":"11","author":"S Khanna","year":"2016","unstructured":"Khanna, S. et al. Malignant mesothelioma effusions are infiltrated by CD3+T cells highly expressing PD-L1 and the PD-L1+tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J. Thorac. Oncol. 11, 1993\u20132005 (2016).","journal-title":"J. Thorac. Oncol."}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41423-019-0245-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41423-019-0245-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41423-019-0245-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:22:00Z","timestamp":1684617720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-019-0245-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,19]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["245"],"URL":"https:\/\/doi.org\/10.1038\/s41423-019-0245-x","relation":{},"ISSN":["1672-7681","2042-0226"],"issn-type":[{"value":"1672-7681","type":"print"},{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,19]]},"assertion":[{"value":"7 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}